Category: GLP-1s

Following jousts between Vermont Sen. Bernie Sanders and Novo Nordisk, the Senate Committee on Health, Education, Labor, and Pensions will vote June 18 on whether to subpoena the drugmaker’s president about the cost of Ozempic and Wegovy. 

Gastric emptying is a critical component to most perioperative care instructions. Now with GLP-1 medications slowing gastric emptying purposefully, researchers are racing to understand how and if the new class of drugs affects surgical procedures. 

There are only two places in the world where semaglutide (Ozempic and Wegovy) is made, and Novo Nordisk is racing against time and high demand to increase supply, Bloomberg reported May 30. 

New York City-based online, direct-to-consumer healthcare company Ro has launched a tool to report and track GLP-1 drug shortages across the U.S., it announced May 29.

Novo Nordisk is contesting Sen. Bernie Sanders’ calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports. 

In a yearslong trial of more than 3,500 participants, Novo Nordisk’s Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke and death. 

Two Eli Lilly manufacturing plants in Indiana are getting a $5.3 billion boost to increase production of Zepbound and Mounjaro, the company said May 24. 

GLP-1s, a popular class of weight loss and diabetes drugs, can hinder the safety of a common gastroenterology procedure, according to a study published in Gastrointestinal Endoscopy.  

GLP-1 drugs’ recent blockbuster appeal has already changed the way providers and pharmacists are doing their jobs, but the American Hospital Association says their appeal could shift other aspects of hospital operations too.

A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association.